Influenza Virus and Epstein-Barr Virus Peptides

Home » What we do » Catalogue Peptides » Influenza virus and Epstein-Barr virus peptides

Influenza virus and Epstein-Barr virus peptides

CEF product	Peptide sequence	Catalog no.	Quantity	GBP
CEF1, Influenza Matrix Protein M1 (58 – 66)	GILGFVFTL	AB-CEF001	1 mg	£105
CEF2, Influenza Virus PA (46 – 54)	FMYSDFHFI	AB-CEF002	1 mg	£105
CEF3, Influenza Virus M1 (13 – 21)	SIIPSGPLK	AB-CEF003	1 mg	£105
CEF4, Influenza Virus NP (342 – 351)	RVLSFIKGTK	AB-CEF004	1 mg	£105
CEF5, Influenza Virus NP (91 – 99)	KTGGPIYKR	AB-CEF005	1 mg	£105
CEF6, Influenza Virus NP	LPFDKTTVM	AB-CEF006	1 mg	£105
CEF7, Influenza Virus NP (380 – 388)	ELRSRYWAI	AB-CEF007	1 mg	£105
CEF8, Influenza Virus NP (383 – 391)	SRYWAIRTR	AB-CEF008	1 mg	£105
CEF9, Influenza Virus M1 128 – 135	ASCMGLIY	AB-CEF009	1 mg	£105
CEF10, Epstein – Barr Virus LMP2 (426 – 434)	CLGGLLTMV	AB-CEF010	1 mg	£105
CEF11, Epstein – Barr Virus BMLF1 (280 – 288)	GLCTLVAML	AB-CEF011	1 mg	£105
CEF12, Epstein – Barr Virus latent NA3B (399 – 408), AVF	AVFDRKSDAK	AB-CEF012	1 mg	£105
CEF14, Epstein – Barr Virus RTA Protein (28 – 37)	DYCNVLNKEF	AB-CEF014	1 mg	£105
CEF15, Epstein – Barr Virus Lytic Cycle Protein BZLF – 1(190 – 197)	RAKFKQLL	AB-CEF015	1 mg	£105
CEF16, Epstein – Barr Virus latent NA – 3A (337 – 347)	FLRGRAYGL	AB-CEF016	1 mg	£105
CEF17, Epstein – Barr Virus latent NA – 3A (158 – 166)	QAKWRLQTL	AB-CEF017	1 mg	£105
CEF18, Epstein – Barr Virus latent NA – 3C (258 – 266)	RRIYDLIEL	AB-CEF018	1 mg	£105
CEF19, Epstein – Barr Virus latent NA – 3A (458 – 466)	YPLHEQHGM	AB-CEF019	1 mg	£105
CEF20, Cytomegalovirus, CMV pp65 (495 – 503)	NLVPMVATV	AB-CEF020	1 mg	£105
CEF21, Cytomegalovirus, CMV pp65 (417 – 426)	TPRVTGGGAM	AB-CEF021	1 mg	£105
CEF22, Cytomegalovirus, CMV pp65 (378 – 389)	SDEEEAIVAYTL	AB-CEF022	1 mg	£105
CEF23, Cytomegalovirus, CMV pp65 (123 – 131)	IPSINVHHY	AB-CEF023	1 mg	£105
CEF24, Influenza Virus PB1 Peptide (591 – 599)	VSDGGPNLY	AB-CEF024	1 mg	£105
CEF25, Influenza Virus NP (44 – 52)	CTELKLSDY	AB-CEF025	1 mg	£105
CEF26, Influenza Virus NP (265 – 274)	ILRGSVAHK	AB-CEF026	1 mg	£105
CEF27, Epstein – Barr Virus BRLF – 1 lytic (148 – 156)	RVRAYTYSK	AB-CEF027	1 mg	£105
CEF28, Epstein – Barr Virus latent NA – 3A (603 – 611)	RLRAEAQVK	AB-CEF028	1 mg	£105
CEF29, Epstein – Barr Virus latent NA – 3B (416 – 424)	IVTDFSVIK	AB-CEF029	1 mg	£105
CEF30, Epstein – Barr Virus BRLF1 (134 – 142)	ATIGTAMYK	AB-CEF030	1 mg	£105
CEF31, Epstein – Barr Virus latent NA – 3A (379 – 387)	RPPIFIRRL	AB-CEF031	1 mg	£105
CEF32, Epstein – Barr Virus latent NA – 3C (281 – 290)	EENLLDFVRF	AB-CEF032	1 mg	£105
CEF33, Cytomegalovirus, HCMV pp65	EFFWDANDIY	AB-CEF033	1 mg	£105

14 May 2025

Fluorescent Peptides: A Guide for Life Science Researchers

Explore key considerations for designing fluorescent peptides, including dye selection, spacers, handling, and storage. Read our guide.

25 March 2025

Peptide Synthesis: An Overview

Peptide synthesis is a cornerstone of modern science, underpinning advances in medicine, biotechnology, and fundamental research that enable the creation of molecules that drive advancements in medicine, research, and technology.

13 February 2024

Peptide Oligonucleotide Conjugates for Life Science Research

The conjugation of peptides to oligos is highly advantageous. It broadens their applications by enhancing them with additional unique properties. Read more.

Influenza and Epstein-Barr virus peptides